Federal Circuit Review - Volume 3 | Issue 5 - May 2013


In This Issue:

• Patent Office Must Prove Prior Art Reference Is Enabling

• Complaint Was Adequate Despite Non-Infringing Possibilities

• FDA Approval Not Relevant to Obviousness Analysis

- Excerpt from Patent Office Must Prove Prior Art Reference Is Enabling:

In In Re Steve Morsa, Appeal No. 12-1609, the Federal Circuit affirmed the Board’s rejection of certain claims as obvious, vacated the Board’s rejection of certain claims as anticipated, and remanded for a proper enablement analysis.

Morsa filed several hundred claims directed to a benefits information database, two of which were rejected as anticipated by a short press release that announced the launch of an Internet-based benefit database product. Morsa appealed the anticipation rejection to the Board, arguing that the press release was not an enabling disclosure. The Board sustained the rejection and subsequently denied two requests for a rehearing on the issue of anticipation...

Please see full newsletter below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Knobbe Martens Olson & Bear LLP | Attorney Advertising

Written by:


Knobbe Martens Olson & Bear LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.